Brokerages expect Calithera Biosciences Inc (NASDAQ:CALA) to report earnings per share (EPS) of ($0.24) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Calithera Biosciences’ earnings. The lowest EPS estimate is ($0.29) and the highest is ($0.19). Calithera Biosciences reported earnings per share of ($0.45) in the same quarter last year, which indicates a positive year-over-year growth rate of 46.7%. The business is scheduled to report its next quarterly earnings results after the market closes on Thursday, March 8th.
On average, analysts expect that Calithera Biosciences will report full-year earnings of ($0.77) per share for the current financial year, with EPS estimates ranging from ($0.83) to ($0.73). For the next fiscal year, analysts expect that the company will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.98) to ($0.45). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for Calithera Biosciences.
Several equities analysts have commented on CALA shares. ValuEngine downgraded shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub downgraded shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 9th. Zacks Investment Research downgraded shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, Citigroup upgraded shares of Calithera Biosciences from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $6.95 to $14.00 in a research note on Friday, February 16th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $16.67.
Several large investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new position in shares of Calithera Biosciences during the second quarter worth $806,000. Vanguard Group Inc. grew its stake in shares of Calithera Biosciences by 29.7% during the second quarter. Vanguard Group Inc. now owns 1,199,525 shares of the biotechnology company’s stock worth $17,813,000 after purchasing an additional 274,510 shares in the last quarter. Dupont Capital Management Corp acquired a new position in shares of Calithera Biosciences during the third quarter worth $258,000. American Century Companies Inc. grew its stake in shares of Calithera Biosciences by 272.8% during the third quarter. American Century Companies Inc. now owns 424,752 shares of the biotechnology company’s stock worth $6,690,000 after purchasing an additional 310,806 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Calithera Biosciences by 705.3% during the second quarter. Wells Fargo & Company MN now owns 26,832 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 23,500 shares in the last quarter. Institutional investors and hedge funds own 68.91% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/03/14/analysts-anticipate-calithera-biosciences-inc-cala-will-post-earnings-of-0-24-per-share.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.